miR-145 targets CDCA3 leading to the suppression of proliferation, EMT, and metastasis of colorectal cancer (138); in upper tract urothelial carcinoma, miR-145 targets ARF6 repressing cell migration, and invasion (139); miR-145 targets WNT2B leading to suppression of cervical cancer progression and metastasis (140); miR-145 targets NF-kB pathway inhibiting invasion and migration of papillary thyroid carcinoma cells (141); miR-145 targets TWIST leading to the inhibition of migration and invasion of colorectal cancer cells (142). Here, ARF6 is linked to differentiated thyroid carcinoma.